Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

被引：0
|
作者：
Benjamin Tan
Adnan Khattak
Enriqueta Felip
Karen Kelly
Patricia Rich
Ding Wang
Christoph Helwig
Isabelle Dussault
Laureen S. Ojalvo
Nicolas Isambert
机构：
[1] Washington University School of Medicine,Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
[2] Fiona Stanley Hospital,undefined
[3] IOB-Quiron,undefined
[4] UVic-UCC,undefined
[5] University of California Davis Comprehensive Cancer Center,undefined
[6] Cancer Treatment Centers of America,undefined
[7] Piedmont Healthcare,undefined
[8] Henry Ford Cancer Institute,undefined
[9] Merck KGaA,undefined
[10] EMD Serono Research & Development Institute,undefined
[11] Inc.,undefined
[12] An affiliate of Merck KGaA,undefined
[13] Poitiers University Hospital,undefined
来源：
Targeted Oncology | 2021年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：435 / 446
页数：11
相关论文
共 50 条
  • [41] Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
    Paz-Ares, L.
    Kim, T. M.
    Vicente, D.
    Felip, E.
    Lee, D. H.
    Lee, K. H.
    Lin, C-C.
    Flor, M. J.
    Di Nicola, M.
    Alvarez, R. M.
    Helwig, C.
    Ojalvo, L. S.
    Gulley, J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S822 - S822
  • [42] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
    Feng, J.
    Chen, J.
    Li, K.
    Li, X.
    Min, X.
    Li, B.
    Lin, L.
    Fang, Y.
    Sun, Y.
    Zhu, B.
    Wang, Q.
    Wang, L.
    Zou, J.
    Liu, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S995 - S995
  • [43] An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
    Fan, Wenlu
    Chen, Yonglu
    Zhou, Zhenxing
    Duan, Wenwen
    Yang, Chengcheng
    Sheng, Shimei
    Wang, Yongwei
    Wei, Xinru
    Liu, Ying
    Huang, Yanshan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [44] M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.
    Kopetz, Scott
    Spira, Alexander I.
    Wertheim, Michael
    Kim, Edward
    Tan, Benjamin R.
    Lenz, Heinz-Josef
    Nikolinakos, Petros
    Rich, Patricia
    Smith, David A.
    Helwig, Christoph
    Dussault, Isabelle
    Ojalvo, Laureen
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [45] Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).
    Cho, Byoung Chul
    Kim, Tae Min
    Vicente, David
    Felip, Enriqueta
    Lee, Dae Ho
    Lee, Ki Hyeong
    Lin, Chia-Chi
    Flor, Maria Jose
    Di Nicola, Massimo A.
    Alvarez, Rosa Maria
    Dussault, Isabelle
    Helwig, Christoph
    Ojalvo, Laureen S.
    Gulley, James L.
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
    Lind, Hanne
    Gameiro, Sofia R.
    Jochems, Caroline
    Donahue, Renee N.
    Strauss, Julius
    Gulley, James L.
    Palena, Claudia
    Schlom, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [47] A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
    Yang, Yunpeng
    Zhao, Yuangyuan
    Zhou, Ting
    Chen, Gang
    Huang, Yan
    Liu, Feng
    Liu, Zhigang
    Qu, Song
    Lei, Yu
    Chen, Xiaozhong
    Lin, Lizhu
    Fu, Zhichao
    Zhang, Xiaojing
    Yang, Zeyu
    Huang, Chuanpei
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
    Yoo, C.
    Oh, D-Y.
    Choi, H. J.
    Kudo, M.
    Ueno, M.
    Kondo, S.
    Chen, L-T.
    Osada, M.
    Helwig, C.
    Dussault, I.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer
    Bang, Y-J.
    Doi, T.
    Kondo, S.
    Chung, H. C.
    Muro, K.
    Dussault, I.
    Helwig, C.
    Osada, M.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Preclinical evaluation of 89Zr-Df-radiolabeled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
    Burvenich, Ingrid
    Goh, Yit Wooi
    Guo, Nancy
    Gan, Hui
    Rigopoulos, Angela
    Liu, Zhanqi
    Ackermann, Uwe
    Wichmann, Christian
    McDonald, Alexander
    O'Keefe, Graeme
    Gong, Sylvia
    Scott, Fiona
    Li, Linghui
    Geng, Wanping
    Zutshi, Anup
    Lan, Yan
    Scott, Andrew
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
12345